Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 9;39:235. doi: 10.1186/s13046-020-01739-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020, corrected publication 2023

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — MYLK-AS1 and E2F7 overexpression is positively correlated with HCC progression and poor prognosis. a-c Relative expression of MYLK-AS1, miR-424-5p and E2F7 detected by qRT-PCR in 156 paired HCC cancer tissues and matched normal liver tissues. Results are presented as the relative expression (compare to internal control, the 2-△△CT method) in tumor tissues and peritumoral tissues. d MYLK-AS1 expression in peritumoral tissues and HCC tissues by ISH. e Relative MYLK-AS1 expression by qRT-PCR in 156 HCC tissues. Relative MYLK-AS1 expression presented as the relative expression (compare to internal control, the 2-△△CT method) in tumor tissues and the matched normal tissues. HCC patients were divided into high (n = 78) and low (n = 78) group according to the median value (0.50). f-g Relative MYLK-AS1 expression in HCC with different size and stage. Results were presented as the relative expression (compare to internal control, the 2-△△CT method) in tumor tissues and normal tissues. h-i Kaplan-Meier plots of the OS and PFS of HCC patients with high (n = 78) and low (n = 78) MYLK-AS1 expression. Data are presented as mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001. j ROC analysis of the performance of MYLK-AS1 expression of 1-year OS in all patients. K Kaplan-Meier plots of the PFS of HCC patients after postoperative adjuvant TACE therapy with high (n = 36) and low (n = 36) MYLK-AS1 expression. Data are presented as mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001